http://deaandeelhouder.nl/news/2016/2/9 ... ikaanse_m/" onclick="window.open(this.href);return false;
Dit kan de volgende zijn
http://www.bnn.ba/zdravlje/genetski-tes ... upan-u-bih" onclick="window.open(this.href);return false;
Word gratis lid op Beursig.com
Discussieer met duizenden beleggers en profiteer
van minder advertenties en abonneer op onderwerpen.
Geneva, Switzerland – 9th February 2016
Genoma is now present in the South African market. Thanks to a partnership with Intercare’s firm Salubrity, Tranquility and Serenity are now the main players within the predictive medicine market in the Rainbow Nation.
With a population of 54 million, and a birth rate of 2.40, South Africa constitutes a strong market for Genoma’s non-invasive prenatal test “Tranquility” and the breast and ovarian cancer screening test “Serenity”. Thus, the exclusive partnership with a leading provider of integrated healthcare services in South Africa, guarantees a solid start to Genoma’s offering within the country. Indeed, with its 4 day hospitals, 4 sub-acute and rehabilitation hospitals, and 16 medical centres, Intercare is a major player within the South African healthcare system, and so will Genoma.
Genetic counsellors have already been integrated into Intercare’s new wellness company, Salubrity. The goal is to now extend this offering through the incorporation of Genoma’s screening technologies in order to provide a more inclusive, comprehensive and complete healthcare service.
As Intercare CEO Dr Hendrik Hanekom said
Salubrity means conducive or favourable to health or well-being […] this name perfectly encapsulates the principle aim of our new company, which is to make great health possible.
The partnership with Intercare reinforces Genoma’s strategy of becoming a world leader in genetic diagnostics. The launch of Genoma’s products in South Africa represensents its first milestone into the African continent. Genoma conciously sought out a well-established, locally-relevant and patent-focused company in order to ensure appropriate implementation of genetic screening and testing.
Everyone should be able to have access to the most advanced technology for their health because everyone should have access to peace of mind. Genoma is today bringing both to South Africa, and will use this as the basis for further expansion later on.
said CEO Frederic Amar.
ESPERITE keeps growing at an incremental pace and the prospects for Q4 remain positive
the high-growth potential of the new markets is expected to have a positive effect on the results already in Q4.
Genoma continued its sharp growth over the reporting period with a 45% increase compared to Q2. Expectations for Q4 and 2016 are high.
The agreement signed with the John Paul II Foundation for Research and Molipharma, subsidiaries of Catholic University of the Sacred Heart, will show results in Q4. In Spain.(nog niks van gehoord)
Growth for the CryoSave revenue is expected for Q4. Cross-selling strategies between CryoSave and Genoma products and services is showing a positive trend.
Dus volgende week de show voor Amar
Kijken of er nieuws uit de pipeline komt en targets richting 4 euro haalbaar zijn
Huidige stand 2,39
Omzet kent marginale daling naar 27.5 mjn voor 2015 van 27.6 mjn voor 2014
Operationaal resultaat daalt naar -7.5 mjn voor 2015 van -5.1 mjn in 2014
EBITDA lager naar -4.9mjn voor 2015 van -1.1 mjn in 2014
Terug richting de 2 euro en minder....
Duitse peer Vita 34 doet het opmerkelijk beter